MoonLake Immunotherapeutics

Helix Acquisition Corp, listed under ticker HLXA and sponsored by Helix Acquisition Holdings LLC, completed its initial public offering in 2021 with a focus on the biopharmaceutical sector. The 10-Q filed May 21, 2021 covers a quarterly reporting period during the SPAC's pre-combination search phase. In October 2021, Helix announced a business combination with MoonLake Immunotherapeutics AG, a clinical-stage company developing nanobody-based therapies targeting inflammatory diseases such as hidradenitis suppurativa and psoriatic arthritis. The de-SPAC transaction closed in April 2022, with the combined entity continuing to operate as MoonLake Immunotherapeutics in the biopharmaceutical space. Sign up on SpacDesk for full filings history, timeline analytics, and ongoing data coverage on HLXA and the broader SPAC universe.